| Project/Area Number |
15591412
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | KYUSHU UNIVERSITY |
|---|
Principal Investigator |
TANAKA Fumiaki Kyushu University, Kyushu Univ.Hospital, Research Associate, 大学病院, 助手 (30332836)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MORI Masaki Kyushu University, Medical Institute of Bioregulation, Professor, 生体防御医学研究所, 教授 (70190999)
UTSUNOMIYA Tohru Kyushu University, Kyushu Univ.Hospital, Assistant Professor, 大学病院, 講師 (30304801)
MIMORI Koshi Kyushu University, Medical Institute of Bioregulation, Research Associate, 生体防御医学研究所, 助手 (50322748)
YOSHIKAWA Yasuji Kyushu University, Kyushu Univ.Hospital, Associate Professor, 大学病院, 助教授 (80124816)
|
|---|
| Project Period (FY) |
2003 – 2004
|
| Project Status |
Completed (Fiscal Year 2004)
|
| Budget Amount *help |
¥3,300,000 (Direct Cost: ¥3,300,000)
Fiscal Year 2004: ¥1,600,000 (Direct Cost: ¥1,600,000)
Fiscal Year 2003: ¥1,700,000 (Direct Cost: ¥1,700,000)
|
|---|
| Keywords | Anticamcer drug / dendritic cells / Cryotherapy / killer T cells / CD8陽性細胞 |
|---|
| Research Abstract |
We have investigated the in vivo antitumor effects of intratumoral(i.t.) administration of dendritic cells(DC) following low-dose chemotherapy using cisplatin plus 5-FU. Combination of i.t.injection of DC and systemic chemotherapy induced complete rejection of the treated tumor, MC38 murine adenocarcinoma. Furthermore, the antitumor effects were also observed on a distanttumor inoculated in the contralateral flank of the animal. When the 10 times the number of tumor cells were inoculated, the antitumor effect of the combination of DC following chemotherapy was also confirmed, and in comparison to that of DC or chemotherapy alone, thereafter contributed to a greater prolongation of survival. To analyze the mechanisms of the systemic antitumor effect generated in this system, we assessed the cytolytic activity against inoculated tumors. The cytolytic activity of effector cells from treated animals was shown to be tumor specific, and was mainly CD8 and MHC class I (p<0.01) restricted. CD4 and MHC class-II treatment marginally inhibited the cytolytic activity but not significantly (p=0.07,0.08 respectively). The cytolysis of effector cells was more significantly enhanced by the treatment of both DC and chemotherapy, than that of either DC or chemotherapy alone. This study suggests that the strategy of i.t.injection of DC following low-dose chemotherapy could be a powerful weapon to treat patients with cancer in the clinical settings.
|
